Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1242
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has maintained an Overweight rating on Regeneron Pharmaceuticals and raised the price target from $1166 to $1242.
August 23, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has increased its price target for Regeneron Pharmaceuticals from $1166 to $1242, maintaining an Overweight rating. This suggests confidence in the company's future performance.
The increase in price target by Piper Sandler indicates a positive outlook on Regeneron's future performance. Maintaining an Overweight rating suggests that the analyst expects the stock to outperform the market. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100